AGS67E, an Anti-Cd37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-15-0067
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Analysis of Preclinical and Clinical Samples After Treatment With a CD37 Targeting Antibody Drug Conjugate (AGS67E) Support a High Level of CD37 Expression in NHL

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

A Regulatory Role for CD37 in T Cell Proliferation

Journal of Immunology
AllergyImmunology
2004English

Efficacy of an Anti-Cd22 Antibody-Monomethyl Auristatin E Conjugate in a Preclinical Xenograft Model of Precursor B-Cell Acute Lymphoblastic Leukemia

Leukemia and Lymphoma
Cancer ResearchOncologyHematology
2016English

Targeting B-Cell Malignancies With the Beta-Emitting Anti-Cd37 Radioimmunoconjugate 177Lu-Nnv003

European Journal of Nuclear Medicine and Molecular Imaging
MedicineNuclear MedicineRadiologyImaging
2019English

Hydrophilic Monomethyl Auristatin E Derivatives as Novel Candidates for the Design of Antibody-Drug Conjugates

Separations
FiltrationAnalytical ChemistrySeparation
2018English

A Complementary Role for the Tetraspanins CD37 and Tssc6 in Cellular Immunity

Journal of Immunology
AllergyImmunology
2010English

miR-133 Regulates Evi1 Expression in AML Cells as a Potential Therapeutic Target

Scientific Reports
Multidisciplinary
2016English

The Making of a Leukemic Stem Cell: A Novel Role for IKZF2 in AML Stemness and Differentiation

Cell Stem Cell
Molecular MedicineGeneticsCell Biology
2019English

Preliminary Results of a Phase 1 Dose Escalation Study of the First-In-Class Anti-Cd74 Antibody Drug Conjugate (Adc), Stro-001, in Advanced B-Cell Malignancies

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy